Sonoma Pharmaceuticals, Inc. 8-K

What Happened Sonoma Pharmaceuticals (SNOA) filed an 8-K on January 2, 2026 reporting completion of its annual equity grant to employees and non-employee directors. Non-employee directors each received 10,000 stock options with an exercise price set at the closing share price of $3.68 on January 2, 2026; those options vest in three equal tranches on the first, second and third anniversaries of the grant. Executive officers received Restricted Stock Units (RSUs): CEO Amy Trombly received 10,000 RSUs and CFO Jerry Dvonch received 5,000 RSUs. The RSUs vest on the third anniversary of the grant date, or earlier upon a change of control or as otherwise provided in an executive’s employment agreement.

Key Details

• Grant date / filing: January 2, 2026 (annual equity grant reported on Form 8-K).
• Directors: 10,000 options each; exercise price = $3.68 (closing price on Jan 2, 2026).
• Option vesting: three equal tranches on years 1, 2 and 3 after grant.
• Executives: Amy Trombly (CEO) 10,000 RSUs; Jerry Dvonch (CFO) 5,000 RSUs; RSUs vest on the third anniversary or upon a change of control / per employment agreement.

Why It Matters These grants are routine retention and compensation actions that align directors’ and executives’ incentives with shareholders and create potential future equity dilution when options are exercised or RSUs vest. The awards will also result in stock‑based compensation expense the company will disclose in upcoming periodic reports (10-Q/10-K). Investors may watch future filings for the total share impact, expense recognition and any related changes to executive agreements.